Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 289-297

  Matsui, Satoshi ^a   Osada, Shinji ^a   Tomita, Hiroyuki ^a   Komori, Shuji ^a   Mori, Ryutaro ^a   Sanada, Yuichi ^a   Takahashi, Takao ^a   Yamaguchi, Kazuya ^a   Yoshida, Kazuhiro ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

c Met; Colorectal cancer; Hepatocyte growth factor; Liver metastasis; Signal transduction

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; LIVER TUMOR; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CARCINOMA; COLORECTAL TUMOR; EVALUATION; GENETICS; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SECOND CANCER; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR VOLUME;

ANIMALS; CARCINOMA; COLORECTAL NEOPLASMS; HEPATECTOMY; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77954147689     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000677     Document Type: Article

References (43)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
2. Lochan R, White SA and Manas DM: Liver resection for colorectal liver metastasis. Surg Oncol 16: 33-45, 2007.
3. Bengtsson G, Carlsson G, Hafstrom L and Jonsson PE: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141: 586-589, 1981. (Pubitemid 11099239)
4. Bengmark S and Hafström L: The natural history of primary and secondary malignant tumors of the liver. II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. Digestion 2: 179-186, 1969.
5. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG and Vande Woude GF: Mechanism of met oncogene activation. Cell 45: 895-904, 1986.
6. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF and Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-Met proto-oncogene product. Science 251: 802-804, 1991. (Pubitemid 21926175)
7. Birchmeier C and Gherardi E: Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8: 404-410, 1998. (Pubitemid 28458706)
8. Di Renzo MF, Olivero M, Giacomini A, et al: Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1: 147-154, 1995.
9. Takeuchi H, Bilchik A, Saha S, et al: c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9: 1480-1488, 2003. (Pubitemid 36418405)
10. Michalopoulos GK and DeFrances MC: Liver regeneration. Science 276: 60-66, 1997.
11. + regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 98: 416-423, 2007.
12. Euhus DM, Hudd C, LaRegina MC and Johnson FE: Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234, 1986.
13. Shimada T, Mizutani S, Muto T, et al: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98: 6500-6505, 2001. (Pubitemid 32488266)
14. Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F and Takahashi T: The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res 28: 45-50, 2008.
15. Osada S, Saji S and Kuno T: Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol 85: 48-54, 2004.
16. Osada S, Saji S and Takahashi T: A case report of papilla Vater carcinoma showing positive expression of thymidine phosphorylase. Hepatogastroenterology 51: 375-377, 2004.
17. Osada S, Kanematsu M, Imai H, Goshima S and Sugiyama Y: Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg 201: 405-411, 2005. (Pubitemid 41206779)
18. Glunde K, Raman V, Mori N and Bhujwalla ZM: RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65: 11034-11043, 2005. (Pubitemid 41713374)
19. Tomita H, Yamada Y, Oyama T, et al: Development of gastric tumors in Apc(Min/+) mice by the activation of the betacatenin/Tcf signaling pathway. Cancer Res 67: 4079-4087, 2007. (Pubitemid 46815052)
20. Primrose JN: Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut 50: 1-5, 2002. (Pubitemid 34028291)
21. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235: 759-766, 2002.
22. Nordlinger B, Vaillant JC, Guiguet M, Balladur P, Paris F, Bachellier P and Jaeck D: Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 12: 1491-1496, 1994.
23. Stangl R, Altendorf-Hofmann A, Charnley RM and Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet 343: 1405-1410, 1994.
24. Fujita S and Sugano K: Expression of c-Met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 27: 378-383, 1997.
25. Fazekas K, Csuka O, Köves I, Rásó E and Tímár J: Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin Exp Metastasis 18: 639-649, 2000.
26. Wolmark N, Fisher ER, Wieand HS and Fisher B: The relationship of depth of penetration and tumor size to the number of positive nodes in Dukes C colorectal cancer. Cancer 53: 2707-2712, 1984.
27. de Jong KP, Lont HE, Bijma AM, et al: The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology 22: 1263-1272, 1995.
28. Harun N, Nikfarjam M, Muralidharan V and Christophi C: Liver regeneration stimulates tumor metastases. J Surg Res 138: 284-290, 2007.
29. Rashidi B, An Z, Sun FX, Sasson A, Gamagammi R, Moossa AR and Hoffman RM: Minimal liver resection strongly stimulates the growth of human colon cancer in the liver of nude mice. Clin Exp Metastasis 17: 497-500, 1999.
30. Ikeda Y, Matsumata T, Takenaka K, Sasaki O, Soejima K and Sugimachi K: Preliminary report of tumor metastasis during liver regeneration after hepatic resection in rats. Eur J Surg Oncol 21: 188-190, 1995.
31. Rubin C, Gur G and Yarden Y: Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res 15: 66-71, 2005. (Pubitemid 41653969)
32. Komada M and Kitamura N: The Hrs/STAM complex in the downregulation of receptor tyrosine kinases. J Biochem 137: 1-8, 2005. (Pubitemid 40502401)
33. Hay ED: The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 233: 706-720, 2005.
34. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
35. Brabletz T, Jung A, Reu S, et al: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98: 10356-10361, 2001.
36. Vincan E and Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 25: 657-663, 2008.
37. Weidner KM, Arakaki N, Hartmann G, et al: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 88: 7001-7005, 1991. (Pubitemid 21915077)
38. Jiang W, Hiscox S, Matsumoto K and Nakamura T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29: 209-248, 1999. (Pubitemid 29158969)
39. Elliott BE, Hung WL, Boag AH and Tuck AB: The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 80: 91-102, 2002. (Pubitemid 34258657)
40. Zhang A, Wang MH, Dong Z and Yang T: Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. Am J Physiol Renal Physiol 291: F1323-F1331, 2006.
41. Gygi SP, Rochon Y, Franza BR and Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730, 1999. (Pubitemid 29098230)
42. Jiang WG, Lloyds D, Puntis MC, Nakamura T and Hallett MB: Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor. Clin Exp Metastasis 11: 235-242, 1993. (Pubitemid 23138522)
43. Levina V, Su Y, Nolen B, et al: Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 123: 2031-2040, 2008.